Molecular Imaging of Chemokine Receptor CXCR4
Citations Over TimeTop 10% of 2013 papers
Abstract
CXCR4 was found to be expressed by many different types of human cancers and its expression has been correlated with tumor aggressiveness, poor prognosis and resistance to chemotherapy. CXCR4 was also shown to contribute to metastatic seeding of organs that express its ligand CXCL12 and support the survival of these cells. These findings suggest that CXCR4 is a potentially attractive therapeutic target, and several antagonists and antibodies for this receptor were developed and are under clinical evaluation. Quantifying CXCR4 expression non-invasively might aid in prognostication as a mean for personalized therapy and post treatment monitoring. Multiple attempts were done over the recent years to develop imaging agents for CXCR4 using different technologies including PET, SPECT, fluorescent and bioluminescence, and will be reviewed in this paper.
Related Papers
- → Recent advances on the use of the CXCR4 antagonist plerixafor (AMD3100, Mozobil™) and potential of other CXCR4 antagonists as stem cell mobilizers(2010)118 cited
- → Establishment of a novel CCR5 and CXCR4 expressing CD4+ cell line which is highly sensitive to HIV and suitable for high-throughput evaluation of CCR5 and CXCR4 antagonists(2004)53 cited
- → A novel CXCR4 antagonist for hematopoietic stem cell mobilization(2008)22 cited
- Research Progress of HIV-1 Coreceptor-chemokine Receptor(2003)
- Progress of Coreceptors of HIV-1 and Its Inhibitors(2006)